Opens in a new tab
Thursday, 19 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Lenacapavir

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Lenacapavir

7 stories · every one Fact-Checked
Twice-yearly injectable lenacapavir for HIV prevention compared with daily oral F/TDF in the PURPOSE 5 trial.Clinical TrialsGilead Reports Higher PrEP Persistence with Lenacapavir in PURPOSE 5Gilead Sciences reported significantly higher one-year HIV prevention persistence with twice-yearly injectable lenacapavir than daily oral F/TDF in its Phase 2 PURPOSE 5 trial.9 Nov 2026 · 4 min read
Fact-Checked
Dr. Reddy’s twice-yearly injectable generic lenacapavir for HIV preventionGenericsDr. Reddy’s Wins FDA Approval for Generic Lenacapavir Across LMICsDr. Reddy’s Laboratories has secured tentative FDA approval for its generic twice-yearly injectable lenacapavir for HIV prevention.3 Nov 2026 · 4 min read
Fact-Checked
Gilead expands royalty-free lenacapavir licenses for potential once-yearly HIV PrEP accessHealth TidingsGilead Expands Lenacapavir Licenses to Support Potential Once-Yearly HIV PrEP in 120 CountriesGilead Sciences has expanded six royalty-free lenacapavir licensing agreements to cover investigational once-yearly HIV PrEP across 120 high-incidence, resource-limited countries as the Phase 3 PURPOSE 365 trial continues.16 Sep 2026 · 3 min read
Fact-Checked
Generic lenacapavir injection for HIV PrEP in India following CDSCO trial waiver recommendationHealth TidingsCDSCO Expert Committee Recommends Bioequivalence and Phase III Trial Waivers for Generic Lenacapavir PrEPIndia’s CDSCO Subject Expert Committee has recommended bioequivalence and Phase III clinical trial waivers for generic lenacapavir injection for HIV PrEP from Dr Reddy’s Laboratories and Emcure Pharmaceuticals…25 Aug 2026 · 3 min read
Fact-Checked
Gilead Sciences presents long-term Phase 3 PURPOSE trial results for twice-yearly lenacapavir PrEP and once-weekly HIV treatment research at AIDS 2026.Clinical TrialsGilead to Present Long-Term Lenacapavir, ISLEND and HIV Pipeline Data at AIDS 2026Gilead Sciences will showcase new HIV prevention and treatment data at AIDS 2026, including long-term Phase 3 PURPOSE trial results supporting twice-yearly lenacapavir for PrEP, full Phase 3…22 Jul 2026 · 4 min read
Fact-Checked
Gilead_Sciences-Logo.wineHealth TidingsSouth Africa Rolls Out Lenacapavir to Prevent HIVGilead Sciences and global health partners have introduced lenacapavir (Yeztugo®) for HIV prevention in South Africa, marking the first large‑scale rollout of a twice‑yearly injectable PrEP.6 Jun 2026 · 3 min read
Fact-Checked
24433Health TidingsPartnership Capital Fuels Lenacapavir’s Surge into the HIV Prevention FrontlinesGilead Sciences, alongside PEPFAR and The Global Fund, will expand access to lenacapavir, aiming to reach up to 3 million people in high-incidence regions by 2028 while advancing…15 Apr 2026 · 3 min read
Fact-Checked
Page 1 of 1